|Genre:||Health and Food|
|Published (Last):||28 January 2007|
|PDF File Size:||4.74 Mb|
|ePub File Size:||16.79 Mb|
|Price:||Free* [*Free Regsitration Required]|
You can change your ad preferences anytime. Upcoming SlideShare. Like this presentation? Why not share! Embed Size px. Start on. Show related SlideShares at end. WordPress Shortcode. CardioTeca Follow. Full Name Comment goes here. Are you sure you want to Yes No. Alejandra Molineros Arredondo. Show More. No Downloads. Views Total views. Actions Shares. Embeds 0 No embeds. No notes for slide. Betabloqueantes en la Insuficiencia Cardiaca 1. Betabloqueantes en el tratamiento de la Insuficiencia Cardiaca 2.
Aparece disnea con las actividades cotidianas. Aparece disnea con actividades de menor intensidad a las cotidianas. Aparece disnea en reposo. Rev Clin Esp ; You just clipped your first slide! Clipping is a handy way to collect important slides you want to go back to later.
Now customize the name of a clipboard to store your clips. Visibility Others can see my Clipboard. Cancel Save.
2005, Número 6
Hemorragia digestiva alta. Portosystemic collateral formation, particularly at the gastroesophageal junction, is a most serious consequence of portal hypertension. Increased portal pressure is the most significant force underlying gastroesophageal variceal formation, to which end portal pressure estimated from the hepatic venous pressure gradient must reach at least 10 mmHg. Subsequently, splanchnic hyperemia also contributes to variceal development. Portoystemic collaterals result from repermeabilization of pre-extant vessels, vascular remodeling, and angiogenesis. The goal of pre-primary prophylaxis is preventing or delaying the formation of gastroesophageal varices. In experimental models of portal hypertension, early administration of splanchnic vasoconstrictors such as beta-blockers, nitric oxide synthesis inhibitors, or antiangiogenic substances inhibits portosystemic collateral formation.